

Resource Summary Report

Generated by RRID on Aug 4, 2026

PE anti-mouse CD80

RRID:AB_313128

Type: Antibody

Proper Citation

BioLegend Cat# 104707, RRID:AB_313128

Antibody Information

URL: http://antibodyregistry.org/AB_313128

Proper Citation: BioLegend Cat# 104707, RRID:AB_313128

Target Antigen: CD80

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD80

Description: This monoclonal targets CD80

Target Organism: mouse

Clone ID: Clone 16-10A1

Antibody ID: AB_313128

Vendor: BioLegend

Catalog Number: 104707

Alternative Catalog Numbers: 104708

Record Creation Time: 20250820T005429+0000

Record Last Update: 20250820T093103+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD80.

No alerts have been found for PE anti-mouse CD80.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Y, et al. (2025) Neoadjuvant chemotherapy by liposomal doxorubicin boosts immune protection of tumor membrane antigens-based nanovaccine. Cell reports. Medicine, 6(1), 101877.

Xu C, et al. (2025) Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy. Cell reports. Medicine, 6(5), 102078.

Xu Y, et al. (2025) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. Cell.

Song Z, et al. (2025) CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice. Cancer immunology research, 13(8), 1246.

Wang Q, et al. (2025) ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. Cell reports, 44(10), 116314.

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α 1/2 shedding. Cell reports. Medicine, 6(3), 101981.

Amon L, et al. (2025) GM-CSF and specific type 2 cytokines induce CD103⁺ and CD301b⁺ cell states in cDC1s and cDC2s. Cell reports, 44(12), 116589.

Stegmann F, et al. (2024) Legionella pneumophila modulates macrophage functions through epigenetic reprogramming via the C-type lectin receptor Mincle. iScience, 27(9), 110700.

Basavaraja R, et al. (2024) PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies. Cell reports. Medicine, 5(7), 101649.

Mei Y, et al. (2024) IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. Cell reports, 43(3), 113835.

Shang L, et al. (2024) Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. Cell reports. Medicine, 5(7),

101648.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Hori A, et al. (2024) MHC class I-dressing is mediated via phosphatidylserine recognition and is enhanced by polyI:C. *iScience*, 27(5), 109704.

Yeh AC, et al. (2024) Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation. *Immunity*, 57(7), 1648.

Sun Y, et al. (2023) Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity. *Cell reports. Medicine*, 4(12), 101303.

Li Y, et al. (2023) TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia. *iScience*, 26(8), 107451.

Zhao Y, et al. (2023) cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity. *Immunity*.

Lv F, et al. (2022) Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment. *iScience*, 25(1), 103639.

Vogel A, et al. (2022) JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. *Cell reports*, 38(8), 110420.